SCHEMBL1921032

SCHEMBL1921032

O=[C]c1ccc2cc3ccccc3cc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
CYP3A4 P08684 2/20 0.44
HSD17B10 Q99714 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
ALOX15 P16050 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44
HBB P68871 1/20 0.44
HIF1A Q16665 1/20 0.44
CA1 P00915 4/20 0.38
CA2 P00918 4/20 0.38
CYP1A2 P05177 3/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1B1 Q16678 1/20 0.38
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
ASIC3 Q9UHC3 1/20 0.36
CYP2A6 P11509 4/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL69325 0.93 CES2 (0.43) ALDH1A1CYP3A4HSD17B10TDP1CA1
SCHEMBL4022260 0.87 ASIC3 (0.33) CA1CA2CYP1A2CYP1A1CYP1B1
SCHEMBL5182331 0.85 CYP1A2 (0.35) CA1CA2CYP1A2CYP1A1CYP1B1
SCHEMBL1920437 0.80 CYP1A2 (0.61) ALDH1A1HSD17B10TDP1HIF1ACA1
SCHEMBL5572006 0.80 ASIC3 (0.52) ALDH1A1CYP3A4HSD17B10TDP1ALOX15
SCHEMBL5573818 0.80 ASIC3 (0.52) ALDH1A1CYP3A4HSD17B10TDP1ALOX15
SCHEMBL1920223 0.77 ALDH1A1 (0.56) ALDH1A1HSD17B10TDP1HIF1ACA1
SCHEMBL1612913 0.76 ALDH1A1 (0.44) ALDH1A1CYP3A4HSD17B10TDP1ALOX15
SCHEMBL2761110 0.76 CA1 (0.57) ALDH1A1CYP3A4HSD17B10TDP1ALOX15
SCHEMBL11126903 0.76 CYP1A1 (0.56) ALDH1A1CYP3A4HSD17B10TDP1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116813979-A Nucleating agent, synthetic resin composition containing same, and molded article thereof 株式会社ADEKA 2023-09-29 CN disclosed
CN-112839988-B Nucleating agent, synthetic resin composition containing same, and molded article thereof 株式会社ADEKA 2023-06-06 CN disclosed
US-20210395209-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF ADEKA CORPORATION (JP) 2021-12-23 US disclosed
EP-3858909-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF ADEKA CORPORATION (JP) 2021-08-04 EP disclosed
CN-112839988-A Nucleating agent, synthetic resin composition containing same, and molded article thereof 株式会社ADEKA 2021-05-25 CN disclosed
WO-2020067144-A1 NUCLEATING AGNET, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF 株式会社ADEKA 2020-04-02 WO disclosed
US-8394974-B2 Process for producing optically active chromene oxide compound NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2013-03-12 US disclosed
EP-1718629-B1 Benzopyran compounds useful for the treatment of arrhytmia NISSAN CHEMICAL IND LTD (JP) 2012-12-26 EP disclosed
US-8030499-B2 1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-10-04 US disclosed
US-7964623-B2 Tricyclic benzopyrane compound NISSAN CHEMICAL INDUSTRIES LTD. (JP) 2011-06-21 US disclosed
EP-0536936-B1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use SANKYO CO (JP) 1996-08-14 EP disclosed
EP-0542117-B1 Process for the preparation of aryle esters of chloroformic acid BASF AG (DE) 1995-09-13 EP disclosed
US-5376634-A Microbiocides FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1994-12-27 US disclosed
US-5274164-A Preparation of aryl chloroformates BASF AKTIENGESELLSCHAFT (DE) 1993-12-28 US disclosed
EP-0542117-A1 Process for the preparation of aryle esters of chloroformic acid BASF Aktiengesellschaft (DE) 1993-05-19 EP disclosed
EP-0542132-A1 Process for the preparation of aryle esters of chloroformic acid BASF Aktiengesellschaft (DE) 1993-05-19 EP disclosed
EP-0536936-A1 Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use Sankyo Company Limited (JP) 1993-04-14 EP disclosed
EP-0486011-A2 Pharmaceutical composition against Pneumocystis carinii FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1992-05-20 EP disclosed
CN-1059729-A Novel polypeptide compound and preparation method thereof FUJISAWA PHARMACEUTICAL CO (JP) 1992-03-25 CN disclosed
EP-0462531-A2 Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-12-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210395209-A1 NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF NOC2L, RIF1, NAP1L1 ALDH1A1 2699/4885CYP3A4 4408/4885HSD17B10 3823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.